A strategy to simultaneously eradicate the natural reservoirs of rabies and Ebola virus

Gary Wong, Gary Kobinger

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Evaluation of: Blaney JE, Wirblich C, Papaneri AB et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J. Virol. 85(20), 10605-10616 (2011). The efficacy of a recombinant live-attenuated or chemically inactivated bivalent vaccine against rabies virus (RABV) and Ebola virus (EBOV) infection was evaluated in a lethal mouse model of infection. The vaccines were derived from the live-attenuated Street Alabama Dufferin B19 RABV platform already approved for veterinary use, where intramuscular, intranasal and intraperitoneal administration of the recombinant vaccines were avirulent in adult mice. Significant levels of serum RABV- and EBOV-specific antibodies were observed postvaccination, with levels that correlated with protection in vaccinated mice post-RABV or -EBOV challenge. These results justify further studies in guinea pigs and nonhuman primates, and highlight a promising strategy to eradicate the natural reservoirs of RABV and EBOV.

Original languageEnglish (US)
Pages (from-to)163-166
Number of pages4
JournalExpert review of vaccines
Issue number2
StatePublished - Feb 2012
Externally publishedYes


  • Ebola virus
  • bats
  • mice
  • rabies virus
  • reservoir
  • transmission
  • viral vaccine
  • wildlife

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'A strategy to simultaneously eradicate the natural reservoirs of rabies and Ebola virus'. Together they form a unique fingerprint.

Cite this